Posts Tagged ‘Wegovy’

Will Policy Makers or Market Forces Lower GLP-1 Costs First?

March 28, 2024 — A new economic analysis in JAMA Network Open brings unsurprising news: manufacturing costs for GLP-1 agonists are a tiny fraction of the price for these important medicines. This is always the case for innovative prescription drugs that must recover billions of dollars of development costs in order to be profitable. The response from policy makers […]

Opening Medicare to Semaglutide for Obesity and Heart Disease

March 22, 2024 — This is a striking change. Until now, the steadfast refusal of CMS to allow coverage of any obesity medicine by Medicare has been unwavering. Then two weeks ago, FDA granted a new indication for semaglutide for persons with both heart disease and obesity to prevent heart attacks, strokes, and deaths. Now CMS says it’s A-OK […]

Lining Up at Amazon and LillyDirect for Obesity Medicines

March 18, 2024 — Hear that rumble? Nope, it not the latest SpaceX launch. It is the roar of growing demand for obesity care in the U.S. Two pieces of news in the last week remind us of how steep the upward line of growth in obesity treatment is right now. To help it scale up their reach to […]

Indication for Heart Health Marks a New Era in Obesity Treatment

March 9, 2024 — It’s official. FDA now says that semaglutide, in doses used to treat obesity, can prevent heart attacks, strokes, and deaths in persons with cardiovascular disease and overweight or obesity. This is nothing short of the dawn of a new era in obesity treatment. FDA Division Director John Sharretts said it clearly: “This patient population has […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

What Became of Trends We Expected to Shape 2023?

December 11, 2023 — “Prediction is difficult, especially if it’s about the future.” Niels Bohr and Yogi Berra both get credit for this pithy bit of wisdom, but the truth is that the proverbial expression has a Danish origin and an unknown author. So now that wit and wisdom emboldens us to look back at the trends we thought […]

Surprise! People Keep Taking Obesity Meds That Work

December 7, 2023 — It is mildly entertaining to watch people squirm as new obesity medicines disrupt their presumptions about obesity and its treatment. Of course, this squirming comes in many different forms. One expression of it is dismay that many people don’t keep taking obesity meds after a year. “Until compliance for these medications increases,” we’re not going […]

The Catch-Up Game Begins in Obesity and Diabetes Medicines

November 25, 2023 — Two weeks ago, a shift started in the public messaging about semaglutide supply issues that have dogged Novo Nordisk from the very beginning of launching a version of this drug (Wegovy) for obesity. Has the catch-up game in production capacity for obesity and diabetes medicines begun at last in earnest? At the beginning of November, […]

The Fake Line Between Obesity and Other Metabolic Disease

November 13, 2023 — Nestled in the midst of a lot of good news last week was a nasty reminder of a persistent problem. It’s the fake line that people persist in drawing between obesity and other metabolic disease. Lilly did it (with consent from FDA) when they decided to put a different brand name on tirzepatide for obesity. […]

Tirzepatide Approved for Obesity: Will Competition Help?

November 9, 2023 — In an era of tremendous change for obesity care, this is certainly a huge milestone. FDA approved tirzepatide for obesity treatment yesterday and put Lilly in the position to offer serious competition to Novo Nordisk. But the question that matters most to us is simple. How will this competition help people seeking to cope with […]